Nakano H, Sasaki Y, Imaoka S, Furukawa H, Ishikawa O, Kabuto T, Kameyama M, Hiratsuka M, Ohigashi H, Nakamori S
Dept. of Surgery, Center for Adult Diseases, Osaka.
Gan To Kagaku Ryoho. 1995 Sep;22(11):1490-2.
In order to repeat the effective transarterial embolization (TAE) or regional chemotherapy, adjuvant surgical therapies were performed for 25 patients with advanced hepatocellular carcinomas (HCC) having collateral feeders. The procedures involved the reduction of tumors with collateral feeders, permanent decollateralization using silicone rubber sheeting of the liver (WRAP therapy), and combination therapies. The 1-, 3- and 5-year survival rates of the patients after the adjuvant surgery were 67%, 18% and 5%, respectively. The 3- and 5-year survival rates of the patients after the initial TAE or arterial chemotherapy were 57% and 12%, respectively. On the other hand, the 3- and 5-year survival rates of patients who had TAE alone (n = 443) were 29% and 14%, respectively. Consequently, this adjuvant surgical therapy may be a useful palliative treatment for HCC.
为了重复进行有效的经动脉栓塞术（TAE）或区域化疗，对25例伴有侧支供血的晚期肝细胞癌（HCC）患者实施了辅助性外科治疗。手术步骤包括缩小伴有侧支供血的肿瘤、使用肝脏硅胶片进行永久性去侧支化（WRAP治疗）以及联合治疗。辅助性手术后患者的1年、3年和5年生存率分别为67%、18%和5%。初次TAE或动脉化疗后患者的3年和5年生存率分别为57%和12%。另一方面，单纯接受TAE治疗的患者（n = 443）的3年和5年生存率分别为29%和14%。因此，这种辅助性外科治疗可能是一种对HCC有效的姑息性治疗方法。
